Chun-Jen LiuDoctor
Dr. Chun-Jen Liu is a professor of Internal Medicine at the National Taiwan University College of Medicine, the Director of the Hepatitis Research Center at NTUH, and the Chief of both the Division of Gastroenterology and the Clinical Trial Center. His research expertise and academic interests include viral hepatitis, metabolic dysfunction-associated steatotic liver disease, liver cirrhosis, and hepatocellular carcinoma. In recent years, Dr. Liu has been actively involved in advanced clinical trials for hepatitis and liver cancer therapies, achieving significant results and earning a strong reputation in the field nationally and internationally. His recent research focus also includes exploring the relationship between metabolic diseases and liver disease.
- Publications
- LIU CJ, CHEN PJ, LAI MY, KAO JH, CHANG CF, WU HL, SHAU WY, CHEN DS. A PROSPECTIVE STUDY CHARACTERIZING FULL-LENGTH HEPATITIS B VIRUS GENOMES DURING ACUTE EXACERBATION. GASTROENTEROLOGY 2003;124:80-90.
- LIU CJ, CHEN PJ, LAI MY, KAO JH, CHEN DS. RIBAVIRIN AND INTERFERON IS EFFECTIVE FOR HEPATITIS C VIRUS CLEARANCE IN HEPATITIS B AND C DUALLY INFECTED PATIENTS. HEPATOLOGY 2003;37:568-576.
- LIU CJ, LEE PH, LIN DY, WU CC, JENG LB, LIN PW, MOK KT, LEE WC, YEH HZ, HO MC, YANG SS, LEE CC, YU MC, HU RH, PENG CY, LAI KL, CHANG SC, CHEN PJ. HEPARANASE INHIBITOR PI-88 AS ADJUVANT THERAPY FOR HEPATOCELLULAR CARCINOMA AFTER CURATIVE RESECTION: A RANDOMIZED PHASE II TRIAL FOR SAFETY AND DOSE-FINDING. J HEPATOL 2009;50:958-968.
- LIU CJ, CHUANG WL, LEE CM, YU ML, LU SN, WU SS, LIAO LY, CHEN CL, KUO HT, CHAO YC, TUNG SY, YANG SS, KAO JH, LIU CH, SU WW, LIN CL, JENG YM, CHEN PJ, CHEN DS. PEGINTERFERON ALFA-2A PLUS RIBAVIRIN FOR THE TREATMENT OF DUAL CHRONIC INFECTION WITH HEPATITIS C AND B VIRUSES. GASTROENTEROLOGY 2009;136:496-504.
- LIU CJ, CHU YT, SHAU WY, KUO RNC, CHEN PJ, LAI MS. TREATMENT OF PATIENTS WITH DUAL HEPATITIS C AND B BY PEGINTERFERON ALFA AND RIBAVIRIN REDUCED RISK OF HEPATOCELLULAR CARCINOMA AND MORTALITY. GUT 2014;63:506-514.
- LIU CJ, CHUANG WL, SHEEN IS, WANG HY, CHEN CY, TSENG KC, CHANG TT, MASSETTO B, YANG JC, YUN C, KNOX SJ, OSINUSI A, CAMUS G, JIANG D, BRAINARD DM, MCHUTCHISON JG, HU TH, HSU YC, LO GH, CHU CJ, CHEN JJ, PENG CY, CHIEN RN, CHEN PJ. EFFICACY OF LEDIPASVIR AND SOFOSBUVIR TREATMENT OF HCV INFECTION IN PATIENTS COINFECTED WITH HBV. GASTROENTEROLOGY 2018;154:989-997.
- LIU CJ, SHEEN IS, CHEN CY, CHUANG WL, WANG HY, TSENG KC, CHANG TT, YANG J, MASSETTO B, SURI V, CAMUS G, JIANG D, ZHANG F, GAGGAR A, HU TH, HSU YC, LO GH, CHU CJ, CHEN JJ, PENG CY, CHIEN RN, CHEN PJ. LEDIPASVIR/SOFOSBUVIR FOR PATIENTS COINFECTED WITH CHRONIC HEPATITIS C AND HEPATITIS B IN TAIWAN: FOLLOW-UP 108 WEEKS POSTTREATMENT. CLIN INFECT DIS 2021 DEC 2:CIAB971.
- CHENG PN, LIU CJ, CHEN CY, TSENG KC, LO CC, PENG CY, LIN CL, CHIU HC, CHIU YC, CHEN PJ. ENTECAVIR PREVENTS HBV REACTIVATION DURING DIRECT ACTING ANTIVIRALS FOR HCV/HBV DUAL INFECTION: A RANDOMIZED TRIAL. CLIN GASTROENTEROL HEPATOL 2021 DEC 2:S1542-3565(21)01270-2. (CORRESPONDING AUTHOR)
